Martin Reck, MD

Martin Reck, MD, Department of Thoracic Oncology, Lung Clinic Grosshansdorf, discusses the IMpower150 trial data for patients with non—small cell lung cancer (NSCLC).

The IMpower150 trial was the first investigation on the combination of chemotherapy, antiangiogenic treatment, and immunotherapy, says Reck in an interview during the 2018 European Lung Cancer Congress, which is a joint collaboration between ESMO and the IASLC. There is good evidence to suggest that there is a synergistic mechanism between antiangiogenic treatment, chemotherapy, and immunotherapy.

Previous data demonstrated that the combination of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel delayed progression or death by 38% compared with bevacizumab and chemotherapy alone for patients with nonsquamous NSCLC.

This is a very intensive treatment, Reck explains. Patients are receiving chemotherapy, bevacizumab, and immunotherapy, so one needs to be aware of the adverse events associated with this combination. Therefore, patients must be selected carefully for this treatment but overall the tolerability was as expected, explains Reck.

Videos

Martin Reck, MD, Department of Thoracic Oncology, Lung Clinic Grosshansdorf, discusses the IMpower150 trial data for patients with non

Dr. Reck on the Rationale of the IMpower150 Trial in NSCLC

Martin Reck, MD, Department of Thoracic Oncology, Lung Clinic Grosshansdorf, discuses the REVEL trial, a randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer (NSCLC).

A significant improvement in overall survival in favor of the combination of docetaxel with ramucirumab, says Reck. An improvement in progression-free survival (PFS) and response rate was also observed.

This important in efficacy was seen independent from histology. An additional analysis was performed on patients who were chemotherapy refractory patients. An additional benefit was seen in this poor prognostic group, said Reck.

Author | Martin Reck, MD

Articles

Dr. Reck on the Rationale of the IMpower150 Trial in NSCLC

Dr. Martin Reck on Docetaxel/Ramucirumab in NSCLC